Growth in the Concurrent Use of Antipsychotics With Other Psychotropic Medications in Medicaid-Enrolled Children
Objective Second-generation antipsychotics (SGAs) have increasingly been prescribed to Medicaid-enrolled children; however, there is limited understanding of the frequency of concurrent SGA prescribing with other psychotropic medications. This study describes the epidemiology of concurrent SGA use w...
Gespeichert in:
Veröffentlicht in: | Journal of the American Academy of Child and Adolescent Psychiatry 2014-09, Vol.53 (9), p.960-970.e2 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 970.e2 |
---|---|
container_issue | 9 |
container_start_page | 960 |
container_title | Journal of the American Academy of Child and Adolescent Psychiatry |
container_volume | 53 |
creator | Kreider, Amanda R., BS, BA Matone, Meredith, MHS Bellonci, Christopher, MD dosReis, Susan, PhD Feudtner, Chris, MD, PhD, MPH Huang, Yuan-Shung, MS Localio, Russell, PhD Rubin, David M., MD, MSCE |
description | Objective Second-generation antipsychotics (SGAs) have increasingly been prescribed to Medicaid-enrolled children; however, there is limited understanding of the frequency of concurrent SGA prescribing with other psychotropic medications. This study describes the epidemiology of concurrent SGA use with 4 psychotropic classes (stimulants, antidepressants, mood stabilizers, and α-agonists) among a national sample of Medicaid-enrolled children and adolescents 6 to 18 years old between 2004 and 2008. Method Repeated cross-sectional design was used, with national Medicaid Analytic eXtract data (10.6 million children annually). Logit and Poisson regression, standardized for year, demographics, and Medicaid eligibility group, estimated the probability and duration of concurrent SGA use with each medication class over time and examined concurrent SGAs in relation to clinical and demographic characteristics. Results While SGA use overall increased by 22%, 85% of such use occurred concurrently. By 2008, the probability of concurrent SGA use ranged from 0.22 for stimulant users to 0.52 for mood stabilizer users. Concurrent SGA use occurred for long durations (69%–89% of annual medication days). Although the highest users of concurrent SGA were participants in foster care and disability Medicaid programs or those with behavioral hospitalizations, the most significant increases over time occurred among participants who were income-eligible for Medicaid (+13%), without comorbid ADHD (+15%), were not hospitalized (+13%), and did not have comorbid intellectual disability (+45%). Conclusion Concurrent SGA use with other psychotropic classes increased over time, and the duration of concurrent therapy was consistently long term. Concurrent SGA regimens will require further research to determine efficacy and potential drug–drug interactions, given a practice trend toward more complex regimens in less-impaired children/adolescents. |
doi_str_mv | 10.1016/j.jaac.2014.05.010 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1566838389</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0890856714003980</els_id><sourcerecordid>1556284300</sourcerecordid><originalsourceid>FETCH-LOGICAL-c542t-9e0f8f3823f6e7579a17faf92709f4b611b567d4ae0e24e65f88d24b7dc550023</originalsourceid><addsrcrecordid>eNqNklGL1DAUhYMo7rj6B3yQgC--tN6kSZuCCMuwrsLKCrr4GDrpDZOxk9SkVebfm9JVYR9E8hASvnPg3HMJec6gZMDq14fy0HWm5MBECbIEBg_IhkneFFIw9ZBsQLVQKFk3Z-RJSgcAYI1Sj8kZl0wywdoNGa9i-DntqfN02iPdBm_mGNFP9DYhDZZe-MmN6WT2YXIm0a8uwzcZjfTT-hvD6Az9iL0z3eSCT4vX-nR9celjGAbs6Xbvhj4bPyWPbDckfHZ3n5Pbd5dftu-L65urD9uL68JIwaeiRbDKVopXtsZGNm3HGtvZljfQWrGrGdvlXL3oEJALrKVVqudi1_RGSgBenZNXq-8Yw_cZ06SPLhkchs5jmJNmsq5VlU_7H6isuRIVQEZf3kMPYY4-B1kMoWqAVTJTfKVMDClFtHqM7tjFk2agl-r0QS_V6aU6DVLn6rLoxZ31vDti_0fyu6sMvFkBzGP74TDqZBx6k0cd0Uy6D-7f_m_vyc3gfG5p-IYnTH9z6MQ16M_L8iy7w0TO3SqofgHAH74B</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1560370135</pqid></control><display><type>article</type><title>Growth in the Concurrent Use of Antipsychotics With Other Psychotropic Medications in Medicaid-Enrolled Children</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kreider, Amanda R., BS, BA ; Matone, Meredith, MHS ; Bellonci, Christopher, MD ; dosReis, Susan, PhD ; Feudtner, Chris, MD, PhD, MPH ; Huang, Yuan-Shung, MS ; Localio, Russell, PhD ; Rubin, David M., MD, MSCE</creator><creatorcontrib>Kreider, Amanda R., BS, BA ; Matone, Meredith, MHS ; Bellonci, Christopher, MD ; dosReis, Susan, PhD ; Feudtner, Chris, MD, PhD, MPH ; Huang, Yuan-Shung, MS ; Localio, Russell, PhD ; Rubin, David M., MD, MSCE</creatorcontrib><description>Objective Second-generation antipsychotics (SGAs) have increasingly been prescribed to Medicaid-enrolled children; however, there is limited understanding of the frequency of concurrent SGA prescribing with other psychotropic medications. This study describes the epidemiology of concurrent SGA use with 4 psychotropic classes (stimulants, antidepressants, mood stabilizers, and α-agonists) among a national sample of Medicaid-enrolled children and adolescents 6 to 18 years old between 2004 and 2008. Method Repeated cross-sectional design was used, with national Medicaid Analytic eXtract data (10.6 million children annually). Logit and Poisson regression, standardized for year, demographics, and Medicaid eligibility group, estimated the probability and duration of concurrent SGA use with each medication class over time and examined concurrent SGAs in relation to clinical and demographic characteristics. Results While SGA use overall increased by 22%, 85% of such use occurred concurrently. By 2008, the probability of concurrent SGA use ranged from 0.22 for stimulant users to 0.52 for mood stabilizer users. Concurrent SGA use occurred for long durations (69%–89% of annual medication days). Although the highest users of concurrent SGA were participants in foster care and disability Medicaid programs or those with behavioral hospitalizations, the most significant increases over time occurred among participants who were income-eligible for Medicaid (+13%), without comorbid ADHD (+15%), were not hospitalized (+13%), and did not have comorbid intellectual disability (+45%). Conclusion Concurrent SGA use with other psychotropic classes increased over time, and the duration of concurrent therapy was consistently long term. Concurrent SGA regimens will require further research to determine efficacy and potential drug–drug interactions, given a practice trend toward more complex regimens in less-impaired children/adolescents.</description><identifier>ISSN: 0890-8567</identifier><identifier>EISSN: 1527-5418</identifier><identifier>DOI: 10.1016/j.jaac.2014.05.010</identifier><identifier>PMID: 25151419</identifier><identifier>CODEN: JAAPEE</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adolescents ; Antipsychotic Agents - therapeutic use ; Attention deficit hyperactivity disorder ; Child ; Children & youth ; Demographics ; Drug Prescriptions - statistics & numerical data ; Epidemiology ; Female ; foster care ; Humans ; Male ; Medicaid ; Medicaid - statistics & numerical data ; pediatric psychopharmacology ; Pediatrics ; Polypharmacy ; Psychiatry ; Psychotropic drugs ; Psychotropic Drugs - therapeutic use ; Regression analysis ; second-generation antipsychotics ; United States - epidemiology</subject><ispartof>Journal of the American Academy of Child and Adolescent Psychiatry, 2014-09, Vol.53 (9), p.960-970.e2</ispartof><rights>American Academy of Child and Adolescent Psychiatry</rights><rights>2014 American Academy of Child and Adolescent Psychiatry</rights><rights>Copyright © 2014 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.</rights><rights>Copyright Lippincott Williams & Wilkins Sep 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c542t-9e0f8f3823f6e7579a17faf92709f4b611b567d4ae0e24e65f88d24b7dc550023</citedby><cites>FETCH-LOGICAL-c542t-9e0f8f3823f6e7579a17faf92709f4b611b567d4ae0e24e65f88d24b7dc550023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0890856714003980$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,30976,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25151419$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kreider, Amanda R., BS, BA</creatorcontrib><creatorcontrib>Matone, Meredith, MHS</creatorcontrib><creatorcontrib>Bellonci, Christopher, MD</creatorcontrib><creatorcontrib>dosReis, Susan, PhD</creatorcontrib><creatorcontrib>Feudtner, Chris, MD, PhD, MPH</creatorcontrib><creatorcontrib>Huang, Yuan-Shung, MS</creatorcontrib><creatorcontrib>Localio, Russell, PhD</creatorcontrib><creatorcontrib>Rubin, David M., MD, MSCE</creatorcontrib><title>Growth in the Concurrent Use of Antipsychotics With Other Psychotropic Medications in Medicaid-Enrolled Children</title><title>Journal of the American Academy of Child and Adolescent Psychiatry</title><addtitle>J Am Acad Child Adolesc Psychiatry</addtitle><description>Objective Second-generation antipsychotics (SGAs) have increasingly been prescribed to Medicaid-enrolled children; however, there is limited understanding of the frequency of concurrent SGA prescribing with other psychotropic medications. This study describes the epidemiology of concurrent SGA use with 4 psychotropic classes (stimulants, antidepressants, mood stabilizers, and α-agonists) among a national sample of Medicaid-enrolled children and adolescents 6 to 18 years old between 2004 and 2008. Method Repeated cross-sectional design was used, with national Medicaid Analytic eXtract data (10.6 million children annually). Logit and Poisson regression, standardized for year, demographics, and Medicaid eligibility group, estimated the probability and duration of concurrent SGA use with each medication class over time and examined concurrent SGAs in relation to clinical and demographic characteristics. Results While SGA use overall increased by 22%, 85% of such use occurred concurrently. By 2008, the probability of concurrent SGA use ranged from 0.22 for stimulant users to 0.52 for mood stabilizer users. Concurrent SGA use occurred for long durations (69%–89% of annual medication days). Although the highest users of concurrent SGA were participants in foster care and disability Medicaid programs or those with behavioral hospitalizations, the most significant increases over time occurred among participants who were income-eligible for Medicaid (+13%), without comorbid ADHD (+15%), were not hospitalized (+13%), and did not have comorbid intellectual disability (+45%). Conclusion Concurrent SGA use with other psychotropic classes increased over time, and the duration of concurrent therapy was consistently long term. Concurrent SGA regimens will require further research to determine efficacy and potential drug–drug interactions, given a practice trend toward more complex regimens in less-impaired children/adolescents.</description><subject>Adolescent</subject><subject>Adolescents</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Attention deficit hyperactivity disorder</subject><subject>Child</subject><subject>Children & youth</subject><subject>Demographics</subject><subject>Drug Prescriptions - statistics & numerical data</subject><subject>Epidemiology</subject><subject>Female</subject><subject>foster care</subject><subject>Humans</subject><subject>Male</subject><subject>Medicaid</subject><subject>Medicaid - statistics & numerical data</subject><subject>pediatric psychopharmacology</subject><subject>Pediatrics</subject><subject>Polypharmacy</subject><subject>Psychiatry</subject><subject>Psychotropic drugs</subject><subject>Psychotropic Drugs - therapeutic use</subject><subject>Regression analysis</subject><subject>second-generation antipsychotics</subject><subject>United States - epidemiology</subject><issn>0890-8567</issn><issn>1527-5418</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqNklGL1DAUhYMo7rj6B3yQgC--tN6kSZuCCMuwrsLKCrr4GDrpDZOxk9SkVebfm9JVYR9E8hASvnPg3HMJec6gZMDq14fy0HWm5MBECbIEBg_IhkneFFIw9ZBsQLVQKFk3Z-RJSgcAYI1Sj8kZl0wywdoNGa9i-DntqfN02iPdBm_mGNFP9DYhDZZe-MmN6WT2YXIm0a8uwzcZjfTT-hvD6Az9iL0z3eSCT4vX-nR9celjGAbs6Xbvhj4bPyWPbDckfHZ3n5Pbd5dftu-L65urD9uL68JIwaeiRbDKVopXtsZGNm3HGtvZljfQWrGrGdvlXL3oEJALrKVVqudi1_RGSgBenZNXq-8Yw_cZ06SPLhkchs5jmJNmsq5VlU_7H6isuRIVQEZf3kMPYY4-B1kMoWqAVTJTfKVMDClFtHqM7tjFk2agl-r0QS_V6aU6DVLn6rLoxZ31vDti_0fyu6sMvFkBzGP74TDqZBx6k0cd0Uy6D-7f_m_vyc3gfG5p-IYnTH9z6MQ16M_L8iy7w0TO3SqofgHAH74B</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Kreider, Amanda R., BS, BA</creator><creator>Matone, Meredith, MHS</creator><creator>Bellonci, Christopher, MD</creator><creator>dosReis, Susan, PhD</creator><creator>Feudtner, Chris, MD, PhD, MPH</creator><creator>Huang, Yuan-Shung, MS</creator><creator>Localio, Russell, PhD</creator><creator>Rubin, David M., MD, MSCE</creator><general>Elsevier Inc</general><general>Elsevier BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20140901</creationdate><title>Growth in the Concurrent Use of Antipsychotics With Other Psychotropic Medications in Medicaid-Enrolled Children</title><author>Kreider, Amanda R., BS, BA ; Matone, Meredith, MHS ; Bellonci, Christopher, MD ; dosReis, Susan, PhD ; Feudtner, Chris, MD, PhD, MPH ; Huang, Yuan-Shung, MS ; Localio, Russell, PhD ; Rubin, David M., MD, MSCE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c542t-9e0f8f3823f6e7579a17faf92709f4b611b567d4ae0e24e65f88d24b7dc550023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adolescents</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Attention deficit hyperactivity disorder</topic><topic>Child</topic><topic>Children & youth</topic><topic>Demographics</topic><topic>Drug Prescriptions - statistics & numerical data</topic><topic>Epidemiology</topic><topic>Female</topic><topic>foster care</topic><topic>Humans</topic><topic>Male</topic><topic>Medicaid</topic><topic>Medicaid - statistics & numerical data</topic><topic>pediatric psychopharmacology</topic><topic>Pediatrics</topic><topic>Polypharmacy</topic><topic>Psychiatry</topic><topic>Psychotropic drugs</topic><topic>Psychotropic Drugs - therapeutic use</topic><topic>Regression analysis</topic><topic>second-generation antipsychotics</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kreider, Amanda R., BS, BA</creatorcontrib><creatorcontrib>Matone, Meredith, MHS</creatorcontrib><creatorcontrib>Bellonci, Christopher, MD</creatorcontrib><creatorcontrib>dosReis, Susan, PhD</creatorcontrib><creatorcontrib>Feudtner, Chris, MD, PhD, MPH</creatorcontrib><creatorcontrib>Huang, Yuan-Shung, MS</creatorcontrib><creatorcontrib>Localio, Russell, PhD</creatorcontrib><creatorcontrib>Rubin, David M., MD, MSCE</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kreider, Amanda R., BS, BA</au><au>Matone, Meredith, MHS</au><au>Bellonci, Christopher, MD</au><au>dosReis, Susan, PhD</au><au>Feudtner, Chris, MD, PhD, MPH</au><au>Huang, Yuan-Shung, MS</au><au>Localio, Russell, PhD</au><au>Rubin, David M., MD, MSCE</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Growth in the Concurrent Use of Antipsychotics With Other Psychotropic Medications in Medicaid-Enrolled Children</atitle><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle><addtitle>J Am Acad Child Adolesc Psychiatry</addtitle><date>2014-09-01</date><risdate>2014</risdate><volume>53</volume><issue>9</issue><spage>960</spage><epage>970.e2</epage><pages>960-970.e2</pages><issn>0890-8567</issn><eissn>1527-5418</eissn><coden>JAAPEE</coden><abstract>Objective Second-generation antipsychotics (SGAs) have increasingly been prescribed to Medicaid-enrolled children; however, there is limited understanding of the frequency of concurrent SGA prescribing with other psychotropic medications. This study describes the epidemiology of concurrent SGA use with 4 psychotropic classes (stimulants, antidepressants, mood stabilizers, and α-agonists) among a national sample of Medicaid-enrolled children and adolescents 6 to 18 years old between 2004 and 2008. Method Repeated cross-sectional design was used, with national Medicaid Analytic eXtract data (10.6 million children annually). Logit and Poisson regression, standardized for year, demographics, and Medicaid eligibility group, estimated the probability and duration of concurrent SGA use with each medication class over time and examined concurrent SGAs in relation to clinical and demographic characteristics. Results While SGA use overall increased by 22%, 85% of such use occurred concurrently. By 2008, the probability of concurrent SGA use ranged from 0.22 for stimulant users to 0.52 for mood stabilizer users. Concurrent SGA use occurred for long durations (69%–89% of annual medication days). Although the highest users of concurrent SGA were participants in foster care and disability Medicaid programs or those with behavioral hospitalizations, the most significant increases over time occurred among participants who were income-eligible for Medicaid (+13%), without comorbid ADHD (+15%), were not hospitalized (+13%), and did not have comorbid intellectual disability (+45%). Conclusion Concurrent SGA use with other psychotropic classes increased over time, and the duration of concurrent therapy was consistently long term. Concurrent SGA regimens will require further research to determine efficacy and potential drug–drug interactions, given a practice trend toward more complex regimens in less-impaired children/adolescents.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25151419</pmid><doi>10.1016/j.jaac.2014.05.010</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0890-8567 |
ispartof | Journal of the American Academy of Child and Adolescent Psychiatry, 2014-09, Vol.53 (9), p.960-970.e2 |
issn | 0890-8567 1527-5418 |
language | eng |
recordid | cdi_proquest_miscellaneous_1566838389 |
source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Elsevier ScienceDirect Journals |
subjects | Adolescent Adolescents Antipsychotic Agents - therapeutic use Attention deficit hyperactivity disorder Child Children & youth Demographics Drug Prescriptions - statistics & numerical data Epidemiology Female foster care Humans Male Medicaid Medicaid - statistics & numerical data pediatric psychopharmacology Pediatrics Polypharmacy Psychiatry Psychotropic drugs Psychotropic Drugs - therapeutic use Regression analysis second-generation antipsychotics United States - epidemiology |
title | Growth in the Concurrent Use of Antipsychotics With Other Psychotropic Medications in Medicaid-Enrolled Children |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A35%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Growth%20in%20the%20Concurrent%20Use%20of%20Antipsychotics%20With%20Other%20Psychotropic%20Medications%20in%20Medicaid-Enrolled%20Children&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Child%20and%20Adolescent%20Psychiatry&rft.au=Kreider,%20Amanda%20R.,%20BS,%20BA&rft.date=2014-09-01&rft.volume=53&rft.issue=9&rft.spage=960&rft.epage=970.e2&rft.pages=960-970.e2&rft.issn=0890-8567&rft.eissn=1527-5418&rft.coden=JAAPEE&rft_id=info:doi/10.1016/j.jaac.2014.05.010&rft_dat=%3Cproquest_cross%3E1556284300%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1560370135&rft_id=info:pmid/25151419&rft_els_id=S0890856714003980&rfr_iscdi=true |